VYKOURA - (EQ 50MG BASE/5ML (EQ 10MG BASE/ML), EQ 350MG BASE/35ML (EQ 10MG BASE/ML), EQ 500MG BASE/50ML (EQ 10MG BASE/ML); SOLUTION)

Generic Name	LEUCOVORIN CALCIUM	**Innovator**	None
Dosage	EQ 50MG BASE/5ML (EQ 10MG BASE/ML), EQ 350MG BASE/35ML (EQ 10MG BASE/ML), EQ 500MG BASE/50ML (EQ 10MG BASE/ML); SOLUTION	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	VYKOURA is a folate analog indicated for: • Rescue after high-dose methotrexate therapy in adult and pediatric patients. • Reducing the toxicity of o methotrexate in adult and pediatric patients with impaired methotrexate elimination or o folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients.• Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. • Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.